GlassScriptPhysician profile
Mandev S Guram
NPI 1922489285
$1,582.65
in general payments reported to CMS, 2019-2025
27 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $125 · 2021: $360 · 2022: $187 · 2023: $188 · 2024: $280 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $413.62 | 2021-2025 | Freestyle Libre 3 |
| Abbvie INC. | $249.56 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $195.99 | 2020-2022 | |
| Medtronic, INC. | $104.57 | 2024-2025 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $76.74 | 2021-2022 | |
| Amgen INC. | $49.81 | 2019-2020 | |
| Amarin Pharma, INC. | $39.70 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $39.00 | 2020 | |
| Novo Nordisk INC | $36.12 | 2021-2024 | Ozempic, Rybelsus |
| Corcept Therapeutics | $32.48 | 2025 | Korlym |
| Pfizer INC. | $31.83 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $31.27 | 2019 | |
| Zyla Life Sciences, INC. | $26.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.07 | 2021 | |
| Upsher-Smith Laboratories LLC | $24.91 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $24.36 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.84 | 2019 | |
| Stryker Corporation | $21.93 | 2025 | Clottriever Bold Catheter |
| Irhythm Technologies, INC. | $18.32 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.96 | 2022 | |
| Intra-Sana Laboratories | $15.85 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Genentech USA, INC. | $15.71 | 2021 | |
| Inari Medical, INC. | $14.84 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Allergan, INC. | $14.76 | 2020 | |
| Cvrx, INC. | $13.45 | 2024 | Barostim Neo System |
| Glaxosmithkline, LLC. | $12.49 | 2022 | |
| Intersect Ent, INC. | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandev Guram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.